Absci
Data as of .
Company facts
-
Founded
2011
-
Headquarters
United States (Vancouver, WA)
Latest funding round
- Round
- Underwritten public offering (including $40M Eli Lilly strategic investment)
- Date
- Jun 24, 2026
- Amount
- $100M
Drug discovery partners
1 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Almirall Pharma
Expanded collaboration (second target),
$650M total potential (upfront not disclosed)
-
Owkin AI biotech
Immunology target partnership,
Terms not disclosed
Big tech ties
Not counted as pharma partners.
-
AMD
AI drug discovery collaboration,
Drugs on the board
- ABS-201
Phase 1/2 registry
Company reports Phase 1/2a; Phase 2 STORYLINE planned
Androgenetic alopecia, a common form of hair loss (women's cohort opened)
- ABS-101 (anti-TL1A)
Phase 1 per company
Inflammatory bowel disease (TL1A)
Recent news
-
Design details for planned Phase 2 STORYLINE trial of ABS-201
-
Priced $100M offering with Eli Lilly participating
-
Positive interim safety data from HEADLINE Phase 1/2a of ABS-201
-
Almirall dermatology collaboration expanded to up to $650M
-
Almirall elected second target in AI drug creation collaboration
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.